Fig. 10From: The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysisForest plot of the meta-analysis showed non-significant difference in main adverse events of CGRP-mAbs compared with placebo. upper (a), respiratory tract infection; (b), nasopharyngitis; (c), nausea; (d), dizziness; (e), injection-site pain; (f), back pain. CGRP-mAbs, monoclonal antibodies to CGRP and its receptor; M-H, Mantel-Haenszel; CI, confidence interval. ★ The significant result was labeled with an asteriskBack to article page